When Regulatory Ambiguity Begins to Influence Enterprise Risk
Regulatory strategy is not a documentation exercise. It is an enterprise risk decision that directly affects timelines, valuation, and market access.
SHOTUNE provides founder-led regulatory leadership to medical device (Class I-III) companies navigating FDA, EU-MDR and global approval pathways where the cost of getting it wrong is no longer acceptable.
What This Protects
- Approval durability and timeline integrity
- Reduced remediation and rework exposure
- Clear, defensible regulator-facing narratives
- Diligence confidence and valuation stability
- Commercial readiness aligned to regulatory posture
Regulatory missteps delay revenue, expand burn, and compress valuation. Governance protects enterprise outcomes.
Escalate Regulatory Strategy When:
- Submissions stall or face repeated regulator objections
- Pathway, classification, or predicate is unclear
- FDA or Notified Body feedback escalates unpredictably
- Prior advice has resulted in rework or lost momentum
- Regulatory posture begins affecting funding or transactions
- Internal teams lack senior regulatory judgment under ambiguity
Escalation restores clarity before exposure becomes material.
Why SHOTUNE
| Alternative | What They Provide | Limitation | What You Actually Need |
|---|---|---|---|
| Large Consulting Firms | Scale and staffing | Diluted accountability | Direct accountability and speed |
| Former Regulators | Interpretation | Advice without execution authority | Strategy + execution ownership |
| Internal RA + Contractors | Operational support | Gaps in senior judgment | Senior escalation authority |
Regulatory decisions cannot always be delegated. That is when SHOTUNE is engaged.
Strategic Scope
FDA, EU MDR, and global pathway strategy
FDA, EU MDR, and global pathway strategy
Pre-Sub / Q-Sub strategy
Regulatory response and change governance
Inspection and diligence defense
Execution is guided by strategy not isolated in documentation.
How We Work
SHOTUNE operates as embedded executive leadership, not a document vendor:
Owns: regulatory strategy, prioritization, risk/tradeoff framing, regulator-facing narrative, cross‑functional alignment.
You own: risk tolerance, board level decisions, resourcing.
Request a Confidential Regulatory Strategy Discussion
Founder Accountability
- All regulatory engagements are personally led by Dr. Shola Sulaimon, former global regulatory and clinical leader at Medtronic, with 18+ years of experience and 70+ CE Mark approvals across high-risk portfolios.
- If regulatory uncertainty is influencing executive risk conversations, escalation requires senior judgment.